Skip to main content

Table 1 Clinical characteristics of training (Moreno) and validation (TCGA) cohorts

From: A 38-gene model comprised of key TET2-associated genes shows additive utility to high-risk prostate cancer cases in the prognostication of biochemical recurrence

Clinical Characteristic Moreno Cohort (FFPE) TCGA Cohort (RP)
Gleason Score No. of patients (%) No. of patients (%)
≤ 6 (3 + 3) 11 (11.00%) 37 (8.75%)
7 (3 + 4) 53 (53.00%) 162 (38.30%)
7 (4 + 3) 22 (22.00%) 101 (23.88%)
≥ 8 14 (14.00%) 158 (37.35%)
Pathological Stage
 pT2 69 (69.00%) 169 (39.95%)
 pT3 2 (2.00%) 0 (0.00%)
 pT3a 6 (6.00%) 138 (32.62%)
 pT3b 9 (9.00%) 104 (24.59%)
 pT4 1 (1.00%) 6 (1.42%)
Lymph Node Invasion
 Present 0 (0%) 60 (14.18%)
 Absent 37 (37.00%) 331 (78.25%)
Surgical Margins
 Positive 39 (39.00%) 116 (27.42%)
 Negative 56 (56.00%) 312 (73.76%)
Age
 Median 61.7 61
 Range 43.0–78.0 41.0–77.0
Pre-operative PSA (ng/uL)
 Median 7.2 7.5
 Range 1.8–72.6 0.7–107
Biochemical Recurrence
 Number of recurrences 49 (49.00%) 43 (10.17%)
 Average follow-up time in years (range) 5.79 (0.06–15.26) 3.07 (0.06–13.76)
Total 100 423